SCHEDULE: Trails Edge Capital Discloses 9.9% Stake in X4 Pharma

Trails Edge Capital Partners and affiliates have disclosed a 9.9% passive ownership stake in X4 Pharmaceuticals, Inc., holding 2,317,153 shares.

Summary

• Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai collectively reported beneficial ownership of 2,317,153 shares of X4 Pharmaceuticals, Inc. common stock.
• This represents 9.9% of the outstanding common stock of X4 Pharmaceuticals, Inc.
• The ownership includes 1,571,478 directly held shares and 745,675 shares underlying prefunded warrants.
• An additional 1,910,069 shares underlying warrants are excluded from beneficial ownership due to an issuance limitation preventing the holder from exceeding 9.99% of outstanding shares upon exercise.
• The ownership percentage is calculated based on 11,408,357 shares outstanding as of August 4, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, and an additional 11,040,776 shares issued subsequently.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a specialized investment firm is generally viewed positively as it signals institutional confidence in the company, although the passive nature limits direct influence.

Positives

• A significant institutional investor, Trails Edge Capital Partners, has taken a 9.9% stake in X4 Pharmaceuticals, indicating potential confidence in the company's prospects.
• The investment is made by a specialized biotechnology fund, Trails Edge Biotechnology Master Fund, LP, suggesting a focused and informed investment decision within the sector.

Negatives

• The beneficial ownership calculation excludes 1,910,069 shares underlying prefunded warrants due to an issuance limitation, which restricts the investor from exceeding 9.99% ownership.

Risks

• The investor's ability to fully exercise all prefunded warrants is limited by a 9.99% beneficial ownership cap, which could restrict their potential upside if the share price increases significantly and they cannot convert all their warrants.

Future Outlook

The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer, indicating a passive investment strategy.

Management Comments

• "The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

The investment by Trails Edge Capital Partners, an investment manager specializing in biotechnology, suggests continued institutional interest in the biotechnology sector, particularly in companies like X4 Pharmaceuticals, which are often characterized by high growth potential and significant R&D investments.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Increased institutional ownership may provide stability and confidence in the company's long-term prospects.
• Company: The investment by a specialized fund validates the company's business model and could enhance its reputation within the investment community.

Next Steps

• NA

Key Dates

Recommendation

The disclosure of a 9.9% passive stake by Trails Edge Capital Partners, a specialized investment firm, suggests a vote of confidence in X4 Pharmaceuticals. While the investment is passive and does not indicate an intent to influence control, it signals institutional interest and potential long-term value, making it a favorable development for the stock.

Keywords

X4 Pharmaceuticals, Trails Edge Capital, Biotechnology, Investment, SEC Filing, Schedule 13G, Common Stock, Shareholding, Institutional Investor, Passive Investment